Repligen Corp. diskutieren
Repligen Corp.
WKN: 870980 / Symbol: RGEN / Name: Repligen Corp / Aktie / Pharmazeutika / Mid Cap /
141,25 €
-1,53 %
Repligen Co. (NASDAQ: RGEN) is now covered by analysts at TD Cowen. They set a "buy" rating and a $200.00 price target on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $180.00 price target on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) had its price target raised by analysts at JPMorgan Chase & Co. from $190.00 to $200.00. They now have an "overweight" rating on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) had its price target raised by analysts at Royal Bank of Canada from $203.00 to $205.00. They now have an "outperform" rating on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating. They now have a $160.00 price target on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) had its price target lowered by analysts at Royal Bank of Canada from $202.00 to $189.00. They now have an "outperform" rating on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $180.00 price target on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen Corporation (NASDAQ: RGEN) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.
Ratings data for RGEN provided by MarketBeat
Repligen Corporation (NASDAQ: RGEN) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $150.00 price target on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen Corporation (NASDAQ: RGEN) is now covered by analysts at Stephens. They set an "overweight" rating and a $160.00 price target on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen Corporation (NASDAQ: RGEN) had its price target lowered by analysts at Wells Fargo & Company from $180.00 to $175.00. They now have an "overweight" rating on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen Corporation (NASDAQ: RGEN) had its price target raised by analysts at Royal Bank Of Canada from $193.00 to $204.00. They now have an "outperform" rating on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen (NASDAQ:RGEN) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $180.00 price target on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen (NASDAQ:RGEN) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating. They now have a $155.00 price target on the stock, up previously from $130.00.
Ratings data for RGEN provided by MarketBeat
Repligen (NASDAQ:RGEN) was given a new $150.00 price target on by analysts at HSBC Holdings plc. They now have a "buy" rating on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen (NASDAQ:RGEN) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Ratings data for RGEN provided by MarketBeat
Repligen (NASDAQ:RGEN) had its price target raised by analysts at Evercore ISI from $155.00 to $175.00. They now have an "outperform" rating on the stock.
Ratings data for RGEN provided by MarketBeat
Neueste Beiträge
Jefferies_Financial_ in M&T Bank Corp. diskutieren